Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Operating Expenses (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Operating Expenses for 17 consecutive years, with $173.0 million as the latest value for Q1 2026.

  • Quarterly Operating Expenses rose 3.67% to $173.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $687.0 million through Jan 2026, up 9.57% year-over-year, with the annual reading at $687.0 million for FY2026, 9.57% up from the prior year.
  • Operating Expenses for Q1 2026 was $173.0 million at Usana Health Sciences, up from $163.6 million in the prior quarter.
  • The five-year high for Operating Expenses was $248.3 million in Q1 2022, with the low at $145.4 million in Q3 2024.
  • Average Operating Expenses over 5 years is $171.2 million, with a median of $166.8 million recorded in 2024.
  • The sharpest move saw Operating Expenses crashed 35.97% in 2022, then increased 13.35% in 2025.
  • Over 5 years, Operating Expenses stood at $159.0 million in 2022, then decreased by 2.79% to $154.5 million in 2023, then increased by 7.96% to $166.8 million in 2024, then dropped by 1.93% to $163.6 million in 2025, then increased by 5.71% to $173.0 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $173.0 million, $163.6 million, and $168.9 million for Q1 2026, Q3 2025, and Q2 2025 respectively.